Breaking Finance News

Canaccord announced Sientra (NASDAQ:SIEN), bumping up its stock price target to $18.00 today

In a report announced on 10/17/2017 Canaccord bumped up the target of Sientra (NASDAQ:SIEN) from $14.00 to $18.00 reporting a possible upside of 0.10%.

On 9/27/2017, Stifel released a statement on Sientra (NASDAQ:SIEN) upped the target price from $11.00 to $14.00 that suggested a downside of -0.07%.

Having a price of $16.30, Sientra (NASDAQ:SIEN) traded -2.76% lower on the day. With the last close up 52.86% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.03% over the same period. SIEN has recorded a 50-day average of $14.33 and a two hundred day average of $10.37. Trade Volume was down over the average, with 34,831 shares of SIEN changing hands under the typical 170,747

See Chart Below


Sientra has a one year low of $6.92 and a one year high of $16.68 The company’s market cap is currently $0.

About Sientra (NASDAQ:SIEN)

Sientra, Inc. is a medical aesthetics company. The Company's primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons. Its breast implants are primarily used in elective procedures, which are generally performed on a cash-pay basis. TRUE Texture provides texturing on the implant shell that is designed to reduce the incidence of malposition, rotation and capsular contracture. The Company also offers breast tissue expanders and a range of other aesthetic and specialty products. The Company offers a range of HSC+ breast implants, including anatomically shaped textured, round textured and round smooth. The Company also offers miraDry system, the device to reduce underarm sweat, odor and permanently reduce hair of all colors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.